Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 3964

Next Previous
X
Search
Drug Profile

REC 3964

Alternative Names: REC 163964; REC-3964

Latest Information Update: 09 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exscientia; Recursion Pharmaceuticals
  • Developer Recursion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Glucosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium difficile infections
  • Phase I Gastroenteritis

Most Recent Events

  • 31 Aug 2024 Phase-II clinical trials in Clostridium difficile infections (Treatment-experienced) (PO) (NCT06536465)
  • 08 Aug 2024 Recursion Pharmaceuticals plans the phase II ALDER trial for Clostridium difficile infections (Treatment-experienced) in October 2024 (NCT06536465)
  • 08 Aug 2024 Recursion Pharmaceuticals and Exscientia agree to co-promote and co-develop REC 3964 for Clostridioides difficile infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top